The MedTech Margin Squeeze

For most of the past decade, the working assumption in medical technology was straightforward: grow the top line, and the margins would follow. Clinical innovation drove premium pricing. Long-cycle contracts locked in recurring revenue. Healthcare was defensive, spending was resilient, and the sector’s appeal to investors rested partly on that predictability.

That assumption is now under strain. A convergence of forces – tariffs, input cost inflation, aggressive procurement reform, hospital budget pressure, and a thickening layer of regulatory costs – has put MedTech margins under structural pressure that revenue growth alone cannot relieve. According to McKinsey’s analysis of the sector, industry margins have fallen below 2019 levels, and only one in four leading MedTech companies is growing profitably above the industry average. Since 2019, gross margins at major players are down 100 to 200 basis points.

The question facing commercial leaders is no longer simply “how do we grow?” It is “where do we grow, at what price, and are we certain we’re keeping what we win?”

The tariff shock

The clearest near-term pressure point is trade policy. The tariff environment of 2025 delivered something unusual in MedTech: direct, quantified hits to gross margin that boards could not ignore. Johnson & Johnson projected a $400 million tariff impact in 2025, concentrated in its medical device segment. Boston Scientific put its exposure at $200 million. Medtronic forecast a charge of $200 million to $350 million. Abbott described a “few hundred million dollar” impact. GE Healthcare revised its full-year earnings guidance downward sharply.

These are not marginal disruptions. For a sector accustomed to treating cost inflation as a manageable background variable, the sudden visibility of tariff exposure—by product category, by supply chain origin, by geography—has been clarifying. Most large companies absorbed the shock without widespread layoffs or deep R&D cuts, which speaks to underlying financial resilience. But the headwind is expected to persist into 2026 and beyond, and smaller and mid-sized players without the balance sheet depth of a Medtronic or J&J face proportionately harder choices.

The complication unique to MedTech is contractual. Unlike consumer goods manufacturers, who can raise prices relatively quickly when input costs rise, MedTech suppliers are often locked into multi-year public tenders and fixed-price hospital contracts. When tariffs, logistics costs, or raw materials move, the price adjustment mechanism is slow, constrained, or absent entirely. The gap between input cost reality and contract price is where margin quietly disappears.

The procurement revolution

While tariffs are the acute story, the deeper structural force is the evolution of how healthcare systems buy. Value-based procurement—the shift from awarding contracts on unit price to evaluating them on clinical outcomes, total cost of care, sustainability, and service reliability—is gaining formal and regulatory momentum across Europe.

MedTech Europe defines value-based procurement as purchasing that focuses on the best patient outcomes at the lowest overall cost of care, looking beyond the price of a device to the value it creates across a treatment pathway. The EU’s existing public procurement directive already enables this approach; the directive was under review in 2025, with pressure to embed value criteria more consistently across member states.

In practice, the shift creates a paradox for suppliers. On one hand, value-based procurement should reward differentiated products with strong clinical evidence over cheaper, commoditised alternatives. On the other, the transition is uneven. Many procurement departments are still building the analytical capability to evaluate value claims rigorously. In the interim, lowest-cost bias persists in commoditised categories, while higher-end products face demands for evidence that many commercial teams are not yet equipped to provide.

The EU’s International Procurement Instrument measure, which came into force on 30 June 2025, adds another dimension. The European Commission’s first use of the IPI tool restricted Chinese medical device suppliers from EU public contracts worth more than €5 million, following an investigation that found 87% of Chinese public procurement tenders had systematically excluded foreign medical devices. Contracts above that threshold represent approximately 60% of the total value of EU medical device procurement—a market worth roughly €100 billion annually. For non-Chinese MedTech companies, the ruling is a competitive opening. But it also underscores how rapidly geopolitical considerations are reshaping procurement dynamics, and how important it is to track policy changes at the country and category level.

The new margin playbook

What does a modern margin preservation strategy actually look like? The companies gaining ground are working on several fronts simultaneously.

Price discipline starts with knowing what is actually happening. That means tracking realised price by account, SKU, geography, and channel—not just list price or awarded tender price. It means setting price floors for strategic accounts, building approval workflows for exceptions, and monitoring whether post-award contract terms are actually being honoured. Country-specific price corridors matter: a global average conceals enormous variation in where pricing power exists and where it is being surrendered.

Tender strategy is evolving from volume-focused to margin-adjusted. The question is not which tenders can be won, but which are worth winning. That requires scoring opportunities by expected margin contribution, not just revenue potential; using historical award data to predict clearing prices before submitting; and identifying markets where the company already has a strong position—where discounting is simply money left on the table. Equally important is the decision not to bid: chasing low-margin tenders consumes commercial capacity that could be directed to more defensible ground.

Portfolio rationalization is under-used as a margin lever. Long-tail SKUs with low velocity, high service burden, and poor tender competitiveness consume disproportionate commercial effort. Rationalising product variants where complexity adds cost without improving win rates directly improves margin mix. The challenge is that these decisions sit at the intersection of commercial, supply chain, regulatory, and finance functions—which is precisely why they tend not to get made.

Value-based selling requires a shift in commercial capability. As procurement criteria evolve, suppliers need evidence packages that connect devices to outcomes, pathway efficiency, operational savings, and sustainability. That is different from the traditional sales motion. It requires pre-built value dossiers for priority products and markets, buyer-specific mapping of procurement criteria, and commercial teams trained to defend price through evidence rather than adjust it through concession.

Finally, contracting structures are due for modernisation. Many MedTech contracts were designed for a world of stable costs and predictable inflation. Indexed pricing, tiered service-level agreements, and defined price-adjustment mechanisms for inflation-sensitive categories are increasingly necessary—not as unusual requests but as standard commercial practice.

From defence to discipline

There is a risk that the language of margin pressure leads to a defensive posture: protect what you have, cut where you can, avoid the hardest fights. That framing is too narrow.

The companies best positioned for the next phase of MedTech are not those retreating to defensible niches. They are those building the commercial infrastructure—data, process, capability—to compete more deliberately. To know which markets they can price with confidence. To enter tenders with evidence, not just price. To understand, at the level of individual accounts and SKUs, whether the commercial effort they are deploying is generating the return they assume.

The margin squeeze is real. But the response to it is less about survival than about upgrading the quality of commercial decision-making across an industry that, until recently, had the luxury of not needing to.